EloraTZP for Obesity

(AMPLIFY-1 Trial)

This trial tests a new combination treatment called EloraTZP, a potential drug, to determine if it aids weight loss in people with obesity more effectively than current options. Researchers compare EloraTZP to other treatments, including tirzepatide, eloralintide, and a placebo (a harmless pill resembling the real treatment). Individuals with a stable weight recently, a BMI of 35 or higher, and difficulty losing weight through diet might be suitable candidates. Participants will engage in the study for about two years. As a Phase 3 trial, this study represents the final step before FDA approval, offering a chance to contribute to a potentially groundbreaking treatment.

Research shows that the EloraTZP treatment, which combines the drugs eloralintide and tirzepatide, is generally well-tolerated by participants. Studies have found significant weight loss in people taking EloraTZP, with one study noting an average loss of up to 23.3% of body weight over 48 weeks. This suggests the treatment is effective, and no serious safety issues have been widely reported.

Tirzepatide, a component of EloraTZP, has been used in other treatments and is known to be safe. Previous studies of tirzepatide alone have examined its long-term safety when used with other medications, and no major safety concerns have been identified.

Eloralintide, the other component, is still under study. So far, it has shown promising results when combined with tirzepatide, with no major side effects reported. Ongoing trials aim to ensure this combination is safe for people.

Researchers are excited about these treatments for obesity because they offer new approaches compared to existing options like lifestyle changes, bariatric surgery, and medications such as orlistat and liraglutide. EloraTZP, in particular, is noteworthy because it targets multiple pathways involved in appetite regulation and energy balance, potentially offering greater weight loss effects. It is administered subcutaneously and includes varied dosing options that could allow for personalized treatment plans. Additionally, Eloralintide introduces a new active ingredient, and tirzepatide is already known for its effectiveness in managing blood sugar and weight in type 2 diabetes, which may translate into promising results for obesity treatment.

This trial will evaluate different treatments for obesity, including EloraTZP, eloralintide, and tirzepatide. Research has shown that EloraTZP, a combination of eloralintide and tirzepatide, aids in weight loss. In earlier studies, participants using EloraTZP lost an average of 23.3% of their weight over 48 weeks. This exceeds the weight loss seen with tirzepatide alone, which can result in up to 21% weight loss over 72 weeks. Eloralintide alone has demonstrated weight loss between 9% and 20%. Together, these treatments help the body manage weight more effectively than a placebo. Participants in this trial will be assigned to different arms to receive either EloraTZP, eloralintide, tirzepatide, or a placebo.⁶⁷⁸⁹¹⁰